BeiGene, Ltd. (BGNE) Reaches $190.48 After 6.00% Down Move; Frontfour Capital Group Has Lowered Its Grace W R & Co Del New (GRA) Holding

June 13, 2018 - By Richard Conner

BeiGene, Ltd. (NASDAQ:BGNE) Logo

The stock of BeiGene, Ltd. (NASDAQ:BGNE) is a huge mover today! The stock decreased 4.11% or $8.17 during the last trading session, reaching $190.48. About 317,455 shares traded. BeiGene, Ltd. (NASDAQ:BGNE) has risen 406.41% since June 13, 2017 and is uptrending. It has outperformed by 393.84% the S&P500. Some Historical BGNE News: ; 16/04/2018 – BEIGENE LTD – LOOK FORWARD TO ADVANCING PAMIPARIB’S DEVELOPMENT IN CHINA AS WELL AS INITIATING A GLOBAL PHASE 3 TRIAL; 09/05/2018 – BeiGene 1Q Loss/Shr $2.03; 10/04/2018 – BEIGENE INITIATES GLOBAL PHASE 2 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED HEPATOCELLULAR CARCINOMA; 01/05/2018 – BeiGene Appoints Xiaobin Wu as General Manager of China and Pres of BeiGene, Ltd; 21/03/2018 BEIGENE LTD BGNE.O : MORGAN STANLEY RAISES TARGET PRICE TO $200 FROM $93; 09/05/2018 – BeiGene 1Q Rev $32.5M; 15/05/2018 – BEIGENE LTD BGNE.O : MORGAN STANLEY RAISES TARGET PRICE TO $207 FROM $200; 09/05/2018 – BEIGENE LTD – REVENUES FOR THREE MONTHS ENDED MARCH 31, 2018 WERE $32.54 MLN, COMPARED TO NIL IN SAME PERIOD IN 2017; 16/04/2018 – BEIGENE-SAW NO DOSE-LIMITING TOXICITIES, FOUND PAMIPARIB TO BE GENERALLY WELL TOLERATED AMONG THE PRE-TREATED PATIENTS WITH OVARIAN, BREAST CANCERS; 15/05/2018 – Point72 Singapore Adds BeiGene, Exits Yum China: 13FThe move comes after 5 months negative chart setup for the $10.23 billion company. It was reported on Jun, 13 by We have $179.05 PT which if reached, will make NASDAQ:BGNE worth $613.50 million less.

Frontfour Capital Group Llc decreased Grace W R & Co Del New (GRA) stake by 29.74% reported in 2018Q1 SEC filing. Frontfour Capital Group Llc sold 18,658 shares as Grace W R & Co Del New (GRA)’s stock rose 6.39%. The Frontfour Capital Group Llc holds 44,085 shares with $2.70M value, down from 62,743 last quarter. Grace W R & Co Del New now has $4.90B valuation. The stock decreased 1.94% or $1.44 during the last trading session, reaching $72.77. About 450,533 shares traded. W. R. Grace & Co. (NYSE:GRA) has declined 0.65% since June 13, 2017 and is downtrending. It has underperformed by 13.22% the S&P500. Some Historical GRA News: ; 10/04/2018 – WR GRACE DECLINES COMMENT ON HONEYWELL SPECULATION; 09/03/2018 Highly rated borrowers drive leveraged loan pricing lower; 24/04/2018 – W. R. GRACE & CO – LICENSED ITS UNIPOL PP PROCESS TECHNOLOGY TO INTER PIPELINE LTD. FOR HEARTLAND PETROCHEMICAL COMPLEX LOCATED IN ALBERTA; 09/05/2018 – Grace Board Designates La Force to Succeed Festa as Chief Executive Officer; 19/04/2018 – DJ W R Grace & Co, Inst Holders, 1Q 2018 (GRA); 14/05/2018 – York Capital Global Advisors Buys New 1.7% Position in WR Grace; 25/04/2018 – W. R. GRACE & CO GRA.N FY2018 SHR VIEW $3.77, REV VIEW $1.87 BLN — THOMSON REUTERS l/B/E/S; 14/05/2018 – WR Grace at Goldman Sachs Basic Materials Conference Tomorrow; 24/04/2018 – Grace Licenses UNIPOL® PP Process Technology to Inter Pipeline; 25/04/2018 – WR Grace 1Q Net $43.4M

Since February 13, 2018, it had 3 insider purchases, and 0 sales for $660,474 activity. $248,520 worth of W. R. Grace & Co. (NYSE:GRA) was bought by Brown Elizabeth C. Blaser Thomas E bought 5,300 shares worth $346,196. 1,000 shares were bought by Cole Keith N, worth $65,758 on Wednesday, February 14.

Frontfour Capital Group Llc increased Berry Global Group Inc (NYSE:BERY) stake by 25,621 shares to 156,745 valued at $8.59M in 2018Q1. It also upped Ashland Global Hldgs Inc stake by 13,541 shares and now owns 158,694 shares. Cabot Corp (NYSE:CBT) was raised too.

Another recent and important W. R. Grace & Co. (NYSE:GRA) news was published by which published an article titled: “Notable Bullish Options Activity in WR Grace & Co. (GRA) Amid M&A Chatter Involving Honeywell Internaional Inc …” on May 23, 2018.

Among 17 analysts covering W. R. Grace & Co (NYSE:GRA), 13 have Buy rating, 0 Sell and 4 Hold. Therefore 76% are positive. W. R. Grace & Co had 38 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was downgraded by Jefferies on Wednesday, November 30 to “Hold”. The stock has “” rating by Susquehanna on Wednesday, April 26. The firm earned “Buy” rating on Wednesday, April 25 by BMO Capital Markets. Robert W. Baird maintained the stock with “Buy” rating in Friday, February 9 report. The rating was maintained by Credit Suisse with “Buy” on Wednesday, April 11. The company was upgraded on Monday, December 12 by Goldman Sachs. The firm earned “Outperform” rating on Thursday, March 24 by Credit Suisse. The firm earned “Neutral” rating on Monday, August 3 by Tigress Financial. Vertical Research initiated W. R. Grace & Co. (NYSE:GRA) rating on Friday, May 26. Vertical Research has “Buy” rating and $81 target. Jefferies maintained it with “Hold” rating and $77.0 target in Wednesday, October 25 report.

Investors sentiment decreased to 0.83 in Q1 2018. Its down 0.51, from 1.34 in 2017Q4. It dropped, as 32 investors sold GRA shares while 87 reduced holdings. 35 funds opened positions while 64 raised stakes. 54.89 million shares or 3.19% less from 56.69 million shares in 2017Q4 were reported. California State Teachers Retirement Systems stated it has 116,254 shares or 0.02% of all its holdings. Gates Capital Incorporated invested in 3.10 million shares or 4.3% of the stock. Tompkins Financial has 0.01% invested in W. R. Grace & Co. (NYSE:GRA). Rbf Cap Limited Liability holds 22,500 shares or 0.16% of its portfolio. Amer International Grp Incorporated owns 1,557 shares. The New York-based Jpmorgan Chase has invested 0% in W. R. Grace & Co. (NYSE:GRA). Price T Rowe Associates Incorporated Md reported 0% stake. Arrowstreet Ltd Partnership holds 207,969 shares or 0.03% of its portfolio. Lifeplan Fincl Grp Incorporated holds 0.01% or 375 shares. Ubs Asset Americas accumulated 170,835 shares or 0% of the stock. Vanguard Gru holds 0.02% in W. R. Grace & Co. (NYSE:GRA) or 5.96 million shares. Earnest Ptnrs Ltd Limited Liability Company invested in 50 shares or 0% of the stock. Iridian Asset Management Lc Ct reported 2.58M shares. Citigroup reported 32,819 shares or 0% of all its holdings. Ameriprise Fincl has invested 0% of its portfolio in W. R. Grace & Co. (NYSE:GRA).

Analysts await W. R. Grace & Co. (NYSE:GRA) to report earnings on July, 26. They expect $0.95 EPS, up 13.10% or $0.11 from last year’s $0.84 per share. GRA’s profit will be $63.93 million for 19.15 P/E if the $0.95 EPS becomes a reality. After $0.82 actual EPS reported by W. R. Grace & Co. for the previous quarter, Wall Street now forecasts 15.85% EPS growth.

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The company has market cap of $10.23 billion. The companyÂ’s clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations. It currently has negative earnings. The Company’s preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications.

More notable recent BeiGene, Ltd. (NASDAQ:BGNE) news were published by: which released: “BeiGene to Present at the Goldman Sachs 39th Annual Global Healthcare Conference” on June 06, 2018, also with their article: “The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs” published on June 10, 2018, published: “These Stocks Have Quadrupled in Just 1 Year” on May 19, 2018. More interesting news about BeiGene, Ltd. (NASDAQ:BGNE) were released by: and their article: “3 Things In Biotech, May 20: You Want Some Good News?” published on May 21, 2018 as well as‘s news article titled: “BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Chinese Patients with Ovarian Cancer” with publication date: May 17, 2018.

Analysts await BeiGene, Ltd. (NASDAQ:BGNE) to report earnings on August, 8. They expect $-2.25 EPS, down 48.03% or $0.73 from last year’s $-1.52 per share. After $-2.03 actual EPS reported by BeiGene, Ltd. for the previous quarter, Wall Street now forecasts 10.84% negative EPS growth.

W. R. Grace & Co. (NYSE:GRA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.